- 71% intracranial objective response rate (iORR) in BriaCell patients with Central Nervous System (CNS) metastases support clinical efficacy of Bria-IMT™, alone and in combination with an immune checkpoint inhibitor (CPI)
- Tumor reductions observed in heavily pretreated patients highlight potential clinical benefit of Bria-IMT™ in managing CNS metastases
Breast cancer metastasis (spread of the cancer) to the CNS presents a significant clinical challenge, often leading to poor prognosis and early death. BriaCell has recently conducted a retrospective analysis in breast cancer patients with CNS metastases enrolled across both its Bria-IMT™ monotherapy and combination therapy with CPI studies and found remarkable clinical responses.
“We have accumulated positive clinical responses in five patients with intracranial metastases, which generally are extremely difficult to treat, and have a very poor prognosis. This antitumor activity furthers our excitement in our ongoing Phase 3 pivotal trial studying the Bria-IMT™ regimen in advanced breast cancer,” stated Dr.
“The CNS tumor reductions demonstrated in five of seven advanced breast cancer patients are particularly compelling given the history of unsuccessful treatment of CNS metastases in this patient population,” stated Dr.
BriaCell Clinical Data in Advanced Metastatic Breast Cancer Patients with CNS Metastases
The Bria-IMT™ Regimen (Alone or Combined with a CPI)
- CNS lesions improved in 71% of patients (5 of 7), supporting clinical efficacy of the Bria-IMT™ regimen
- Findings provide evidence for the efficacy of the Bria-IMT™ regimen, both alone and in combination with CPI, in CNS metastases patients
- Heavily pretreated metastatic breast cancer patients had failed multiple prior treatments including one patient who had failed treatments with 2 antibody-drug conjugates
- Regression of CNS metastatic tumors was observed across all breast cancer subtypes in heavily pretreated patients highlighting the potential of the Bria-IMT™ regimen in managing CNS metastases
BriaCell is adding a pre-planned subgroup analysis of patients with CNS metastases to its pivotal Phase 3 study in advanced metastatic breast cancer patients. This could provide an additional indication for market approval of Bria-IMT™.
About
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those presented in today’s press release, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company's most recent Management’s Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under “Risks and Uncertainties” in the Company's other filings with the Canadian securities regulatory authorities and the
Neither the
Contact Information
Company Contact:
President & CEO
1-888-485-6340
info@briacell.com
Media Relations:
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com
Investor Relations Contact:
CORE IR
investors@briacell.com
Source:
2023 GlobeNewswire, Inc., source